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Abstract 
The current study aimed to determine if probenecid could directly impair the canine P2X7 receptor, a 
ligand-gated cation channel activated by extracellular adenosine 5′-triphosphate (ATP). Patch clamp 
measurements demonstrated that probenecid impairs ATP-induced inward currents in HEK-293 cells 
expressing canine P2X7. Flow cytometric measurements of ethidium + uptake into HEK-293 cells 
expressing canine P2X7 showed that probenecid impairs ATP-induced pore formation in a concentration-
dependent manner, with a half maximal inhibitory concentration of 158 µM. Finally, ELISA measurements 
revealed that probenecid impairs ATP-induced interleukin-1β release in dog blood. In conclusion, this 
study reveals that probenecid can directly impair canine P2X7 activation. 
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The current study aimed to determine if probenecid could directly impair the canine P2X7 
receptor, a ligand-gated cation channel activated by extracellular adenosine 5’-triphosphate 
(ATP). Patch clamp measurements demonstrated that probenecid impairs ATP-induced 
inward currents in HEK-293 cells expressing canine P2X7. Flow cytometric measurements of 
ethidium+ uptake into HEK-293 cells expressing canine P2X7 showed that probenecid 
impairs ATP-induced pore formation in a concentration-dependent manner, with a half 
maximal inhibitory concentration of 158 µM. Finally, ELISA measurements revealed that 
probenecid impairs ATP-induced interleukin-1β release in dog blood. In conclusion, this 
study reveals that probenecid can directly impair canine P2X7 activation. 
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The P2X7 receptor is a trimeric ligand-cation channel activated by extracellular adenosine 5’-
triphosphate (ATP).[1] Activation of this receptor channel allows the rapid flux of Na+, K+ and 
Ca2+, and the opening of a pore to allow the movement of organic cations, including 
fluorescent dyes such as ethidium+, through the plasma membrane.[1] P2X7 is present on 
canine erythrocytes, lymphocytes and monocytes,[2, 3], as well as brain[4, 5] and kidney 
epithelial cells[6] of dogs. Activation of canine P2X7 leads to pro-inflammatory interleukin-
1β (IL-1β) release from monocytes[7] and in whole blood,[8, 9] as well as to phosphatidylserine 
exposure on erythrocytes.[10] Other biological functions of canine P2X7 are yet to be 
reported, but it is likely that P2X7 activation mediates events similar to those observed in 
humans and rodents, where it is emerging as a potential therapeutic target in a range of 
disorders.[11, 12] Thus, for over a decade we have been studying the biology and pharmacology 
of canine P2X7 to determine if this receptor is a genuine therapeutic target in dogs. 
Probenecid (p-(di-n-propylsulfamyl)-benzoic acid; Benemid® or Benuryl®), which 
inhibits organic anion transporters in renal proximal tubes to prevent reuptake of uric acid 
from urine, is predominately used as a second line treatment of gout in humans.[13] 
Probenecid can also be used in dogs to reduce renal excretion to increase the in vivo 
concentrations of some antibiotics,[14] although this seems to be rarely applied in veterinary 
settings. Probenecid can also impair the ATP release channel pannexin-1,[15, 16] which can 
directly interact with human and rodent P2X7.[17, 18] Notably, probenecid can directly impair 
human P2X7 but not rodent P2X7.[19] Moreover, the P2X7 antagonist profile of canine P2X7 
is similar to that of human P2X7.[8, 20, 21] Thus, given the similar pharmacological profiles 
between these two receptors and the potential use of probenecid in dogs, the current study 
aimed to determine if probenecid could also directly impair canine P2X7. 
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Materials and methods 
Chemicals 
DMEM/F12 medium, GlutaMAX, penicillin-streptomycin, OPTI-MEM reduced serum 
medium, Lipofectamine 2000, RPMI-1640 medium and (water soluble) probenecid were 
from Thermo Fisher Scientific. Foetal bovine serum (heat inactivated before use) was from 
Bovogen Biologicals. ATP and lipopolysaccharide (LPS; Escherichia Coli serotype 055:B5) 
were from Sigma-Aldrich. Ethidium bromide and general chemicals were from Amresco. 
 
Cell culture and transfections 
HEK-293 cells were maintained in DMEM/F12 medium containing 10% foetal bovine 
serum, 2 mM GlutaMAX, 100 U/mL penicillin and 10 µg/mL streptomycin at 37oC/5%CO2. 
HEK-293 cells were transiently transfected with canine P2X7 plasmid DNA using 
Lipofectamine 2000 diluted in OPTI-MEM Reduced Serum medium as described.[21] 
 
Channel activity 
To assess P2X7 channel activity, ATP-induced inward currents in P2X7-transfected HEK-
293 cells in low divalent solution (145 mM NaCl, 5 mM KCl, 0.2 mM CaCl2, 13 mM 




To assess P2X7-mediated pore formation, ATP-induced ethidium+ uptake into P2X7-
transfected HEK-293 cells in NaCl medium (145 mM NaCl, 5 mM KCl, 5 mM glucose, 10 




Peripheral blood was collected into lithium heparin tubes (Greiner Bio-One) from three dogs 
(boxer bull terrier cross, bull mastiff cross, or Staffordshire bull terrier), and studied 
according to institutional guidelines (University of Wollongong). ATP-induced IL-1β release 
in whole blood diluted with an equal volume of RPMI-1640 medium and containing a final 
concentration of 100 ng/mL LPS, was performed as described.[9] The amount of IL-1β in cell-
free supernatants was measured using a Canine IL-1β VetSet ELISA (Kingfisher Biotech) 
according to the manufacturer’s instructions. 
 
Statistical analysis 
Data are presented as mean ± SD. Differences between groups were compared with an one-
way analysis of variance (using Tukey's post test) using Prism 5 for Mac OS X (GraphPad 
Software, San Diego, CA, USA) with P < 0.05 considered significant. 
 
Results 
Probenecid impairs canine P2X7 channel activity 
To determine if probenecid could directly impair activation of canine P2X7, P2X7-
transfected HEK-293 cells were treated with probenecid and/or ATP, and inward currents 
measured using whole-cell patch clamp. ATP induced robust inward currents, with similar 
sized currents observed following a second treatment with ATP (Figure 1), demonstrating, 
that under these conditions, the canine P2X7 channel does not undergo run-up or run-down. 
Following washout, co-treatment of cells with probenecid and ATP significantly reduced 
current density by 60 ± 6% (mean ± SD) (Figure 1). Following washout, pre-treatment of 
these cells with probenecid alone for 1 min significantly reduced ATP-induced current 
density by 83 ± 9%, an affect that was readily reversible following a final washout (Figure 1). 
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Probenecid impairs canine P2X7-mediated pore formation 
To determine if probenecid could impair canine P2X7-mediated pore formation, P2X7-
transfected HEK-293 cells were incubated with increasing concentrations of probenecid for 
15 min, and ATP-induced ethidium+ uptake was assessed by flow cytometry. Probenecid 
impaired ATP-induced cation dye uptake in a concentration-dependent manner with near-
maximal inhibition at 10 mM (97 ± 2%) and with a half maximal inhibitory concentration 
(IC50) of 158 µM (Figure 2). 
 
Probenecid impairs canine P2X7-mediated IL-1β release 
To determine if probenecid could impair canine P2X7-mediated IL-1β release, dog blood was 
pre-incubated with LPS for 2 h, and co-incubated in the absence or presence of probenecid 
during the final 15 min. Blood was then co-incubated for a further 30 min in the absence or 
presence of ATP, and the amount of IL-1β in cell-free supernatants assessed by ELISA. In 
the absence of ATP, IL-1β release was minimal and similar in either the absence or presence 
of probenecid (Figure 3). As expected, ATP incubation, in the absence of probenecid, 
significantly increased IL-1β release compared to blood incubated in the absence of ATP 
(Figure 3). Similar to P2X7 channel activity and pore formation, pre-incubation with 
probenecid reduced ATP-induced IL-1β release by 84 ± 13% (Figure 3). 
 
Discussion 
Using whole-cell patch clamp measurements of P2X7 channel activity, the current study 
demonstrated that probenecid directly blocks canine P2X7 activation. This, finding is similar 
to the direct inhibition of human P2X7, but not rodent P2X7, by probenecid.[19] Using flow 
cytometric measurements of P2X7-mediated pore formation, the current study also showed 
	 7 
that probenecid impaired canine P2X7 with an IC50 of 158 µM, which is similar to the IC50 of 
probenecid against human P2X7 (203 µM).[19] The IC50 value for probenecid against canine 
P2X7 was one to four logs greater than the IC50 values observed for specific P2X7 
antagonists against canine P2X7.[8, 20, 21] Similar differences in IC50 values are also observed 
for human P2X7.[22-25] Finally, using a blood-based assay to study IL-1β release, probenecid 
impaired P2X7-mediated IL-1β release by 84%, which is slightly less to that observed 
previously for the P2X7 antagonist, A438079 (97%), using the same assay,[9] albeit at 
different concentrations (5 mM and 50 µM for probenecid and A438079, respectively). 
Combined, the data above indicates that probenecid is a direct but less potent inhibitor of 
canine P2X7 than conventional P2X7 antagonists. 
The inhibition of both canine and human P2X7 by probenecid parallels the ability of 
conventional P2X7 antagonists to block this receptor in both these species.[8, 20, 21] This 
contrasts well-known differences in antagonist selectivity between human and rodent 
P2X7.[22-25] Moreover, probenecid does not impair rat or murine P2X7.[19] Collectively these 
findings suggests a high degree of similarity in the probenecid-binding site between canine 
and human P2X7 compared to that of rodent P2X7, which parallels the greater sequence 
identity between canine and human P2X7 than between rodent and human P2X7.[1] Although 
the probenecid binding site in P2X7 is unknown, crystal structures of giant panda P2X7 with 
structurally different P2X7 antagonists (A740003, A804598, AZ10606120, GW791343 or 
JNJ47965567) reveal a common antagonist-binding pocket in the large extracellular domain 
of P2X7, with antagonist binding mediated predominately by amino acid residues F88, F95, 
F103, M105, F293 and V312.[26] Notably, these amino acid residues are entirely conserved 
between canine and human P2X7, but not rat (L95 and A312), murine (A312) or guinea pig 
(L88 and L95) P2X7 (human P2X7 numbering),[27] providing a possible explanation for the 
similar antagonist profile shared by canine and human P2X7. Moreover, probenecid (286 Da) 
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is similar in size to the aforementioned P2X7 antagonists (315 to 489 Da) allowing the 
possibility that probenecid may also bind to this common antagonist-binding pocket,[26] 
which is also present in human P2X7.[28] 
Findings from the current and previous[19, 29] studies of probenecid have implications 
for the experimental and clinical use of this compound. Experimentally, probenecid can be 
used at 2 to 2.5 mM in vitro to prevent the secretion and sequestration of calcium indicator 
dyes,[30, 31], and to block pannexin-1.[15, 16] Thus, caution should be applied when using 
probenecid to study canine and human P2X7-mediated Ca2+ fluxes, or pannexin-1-mediated 
events associated with P2X7 activation in these species. Pannexin-1 has been identified in 
Madin-Darby kidney cells [32] but it remains to be determined if probenecid can inhibit canine 
pannexin-1. Clinically, standard oral therapeutic doses of probenecid are in the range 250 mg 
to 2 g twice per day,[33] with mean peak plasma concentrations of probenecid of 35, 70 and 
149 µg/mL 3 to 4 h following single oral doses of 500 mg, 1 g or 2 g, respectively.[34] Thus, 
given that the IC50 values of probenecid against canine and human P2X7 are approximately 
160 and 200 µM (or 46 and 57 µg/mL), respectively, P2X7 may be an off-target of 
probenecid in vivo, at least in the circulation. It remains questionable if probenecid reaches 
sufficiently high enough concentrations to impair P2X7 activation within tissues. Curiously, 
monosodium urate crystals can induce ATP release from murine macrophages to promote IL-
1β release, a process impaired by P2X7 antagonists,[35] suggesting a role for P2X7 activation 
in gout[36]. Thus, the possibility remains that probenecid may at least partially block this 
process in gout. 
 
Conclusion 
In conclusion, the current study demonstrates that probenecid can directly impair canine 
P2X7 activation. Furthermore, probenecid can be added to the list of compounds that impair 
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both canine and human P2X7, which indirectly suggests that the antagonist-binding pocket 
may be quite similar between these two receptors. Finally, caution needs to be applied when 
using probenecid for experimental applications, such as reducing calcium indicator dye 
leakage, in studies relating to canine or human P2X7 activation. 
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Figure 1. Probenecid impairs canine P2X7 channel activity. (A, B) HEK-293 cells, 
transiently transfected with canine P2X7 plasmid DNA, were clamped at -60 mV at room 
temperature. Then 1 mM probenecid (PRO) and/or 250 µM ATP in low divalent solution (as 
indicated) was applied using a fast-flow delivery system and whole cell currents were 
recorded. (A) Inward currents to: ATP alone; ATP alone (repeat); ATP plus PRO; 1 min 
treatment with PRO followed by ATP plus PRO; and ATP alone, respectively. Bars indicate 
5 s exposures; traces are representative of five to eight cells. (B) Results are mean ± SD of 
current density during first ATP exposure, ATP plus PRO exposure, and PRO (1 min pre-
incubation) plus ATP exposure (n=6-8); *P < 0.05 and **P < 0.01 compared to ATP. 
Figure 2. Probenecid impairs canine P2X7-mediated pore formation. HEK-293 cells, 
transiently transfected with canine P2X7 plasmid DNA, in NaCl medium were pre-incubated 
in the absence or presence of PRO as indicated for 15 min at 37oC, before addition of 25 µM 
ethidium+, and incubation in the absence or presence of 250 µM ATP for 5 min. Incubations 
were stopped and ethidium+ uptake determined by flow cytometry. Ethidium+ uptake is 
expressed as percent of maximal ATP response in the absence of PRO. Results are mean ± 
SD (n=3). 
Figure 3. Probenecid impairs canine P2X7-mediated IL-1β release. Dog blood diluted with 
an equal volume of RPMI-1640 medium was incubated in the presence of 100 ng/mL LPS for 
2 h at 37oC, and during the final 15 min samples were incubated in the absence or presence of 
5 mM PRO. Samples were then incubated for a further 30 min in the absence or presence of 6 
mM ATP. The amount of IL-1β release in cell-free supernatants was determined by ELISA. 
Results are mean ± SD (n=3); *P < 0.05, compared to LPS alone; †P < 0.05 compared to LPS 
and ATP. 



